Background Bone metastasis is a prevalent complication of malignant tumors, often resulting in restricted mobility, severe pain, and diminished quality of life. Objective This study aimed to assess the analgesic effect and safety of a co-ablation system that combines elements of hyperthermic ablation and cryoablation in patients with bone metastases. Methods This retrospective study included patients with histologically confirmed painful bone metastases treated with the co-ablation system between January and October 2024. Pain intensity was assessed using the numerical rating scale (NRS), and functional status was evaluated using the Karnofsky Performance Status score at baseline and during a 12-week follow-up. Technical success, adverse events, analgesic use, and pain response (defined as a ≥2-point reduction in NRS) were analyzed. Results Nine patients were included. Technical success was achieved in all procedures, with no procedure-related adverse events observed. Median NRS scores decreased progressively from 5 (IQR 4-6) at baseline to 2 (IQR 1-3) at 12 weeks. By the fourth week, 8 (88.9%) patients achieved a clinically meaningful pain reduction. Karnofsky Performance Status scores showed gradual improvement during follow-up. No patients required escalation of analgesic therapy, and some experienced dose reductions. Conclusions The co-ablation system appeared to be feasible and was associated with short-term pain reduction in patients with bone metastases, with no ablation-related adverse events observed.
Yuan et al. (Thu,) studied this question.